Aleglitazar
Aleglitazar structure
|
Common Name | Aleglitazar | ||
|---|---|---|---|---|
| CAS Number | 475479-34-6 | Molecular Weight | 437.50800 | |
| Density | 1.29 | Boiling Point | 665.151ºC at 760 mmHg | |
| Molecular Formula | C24H23NO5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 356.071ºC | |
Use of AleglitazarAleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)Target: PPARα/γAleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. |
| Name | (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)Target: PPARα/γAleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. |
|---|---|
| Related Catalog | |
| Target |
PPARγ:19 nM (IC50) PPARα:38 nM (IC50) |
| References |
| Density | 1.29 |
|---|---|
| Boiling Point | 665.151ºC at 760 mmHg |
| Molecular Formula | C24H23NO5S |
| Molecular Weight | 437.50800 |
| Flash Point | 356.071ºC |
| Exact Mass | 437.13000 |
| PSA | 110.03000 |
| LogP | 5.12830 |
| Index of Refraction | 1.627 |
| Storage condition | 2-8℃ |
|
~99%
Aleglitazar CAS#:475479-34-6 |
| Literature: US2005/70714 A1, ; Page/Page column 10 ; |
|
~72%
Aleglitazar CAS#:475479-34-6 |
| Literature: US2010/249428 A1, ; Page/Page column 10 ; |
|
~%
Aleglitazar CAS#:475479-34-6 |
| Literature: WO2013/181384 A1, ; Paragraph 0069; 0070; 0071; 0072 ; |
|
~%
Aleglitazar CAS#:475479-34-6 |
| Literature: US2003/55265 A1, ; |
![(Z)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-acrylic acid structure](https://image.chemsrc.com/caspic/375/849150-55-6.png)
![(2R)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid structure](https://image.chemsrc.com/caspic/213/849150-59-0.png)
![(S)-4-Benzyl-3-((2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionyl)-oxazolidin-2-one structure](https://image.chemsrc.com/caspic/435/475480-89-8.png)
| UNII-41T4OAG59U |
| R-1439 |
| Aleglitazar |